ES2179098T3 - Agente de prevencion o de tratamiento de la osteoporosis. - Google Patents

Agente de prevencion o de tratamiento de la osteoporosis.

Info

Publication number
ES2179098T3
ES2179098T3 ES95910802T ES95910802T ES2179098T3 ES 2179098 T3 ES2179098 T3 ES 2179098T3 ES 95910802 T ES95910802 T ES 95910802T ES 95910802 T ES95910802 T ES 95910802T ES 2179098 T3 ES2179098 T3 ES 2179098T3
Authority
ES
Spain
Prior art keywords
osteoporosis
prevent
treatment agent
treat
osteoporosis prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95910802T
Other languages
English (en)
Inventor
Atsutane Ohta
Toshio Takizawa
Takashi Adachi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meiji Seika Kaisha Ltd
Original Assignee
Meiji Seika Kaisha Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=13389532&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2179098(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Meiji Seika Kaisha Ltd filed Critical Meiji Seika Kaisha Ltd
Application granted granted Critical
Publication of ES2179098T3 publication Critical patent/ES2179098T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

MATERIAL PARA PREVENIR Y TRATAR LA OSTEOPOROSIS QUE SE CARACTERIZA POR CONTENER MINERALES Y OLIGOSACARIDOS INDIGERIBLES. ESTE MATERIAL PARA PREVENIR Y TRATAR LA OSTEOPOROSIS ES EXCELENTE PARA LA ABSORCION DEL CALCIO, REDUCIENDOSE LA CANTIDAD DE SAL OSEA QUE SE OBSERVA EN LA OSTEOPOROSIS. DE ACUERDO CON ESTO, LA UTILIZACION DEL MATERIAL PARA PREVENIR Y TRATAR LA OSTEOPOROSIS A QUE HACE REFERENCIA ESTE INVENTO, PERMITE PREVENIR Y RETRASAR LA EVOLUCION DE FORMA EFECTIVA DE LA OSTEOPOROSIS QUE AFECTA PARTICULARMENTE A LAS MUJERES POSTMENOPAUSICAS.
ES95910802T 1994-03-15 1995-03-13 Agente de prevencion o de tratamiento de la osteoporosis. Expired - Lifetime ES2179098T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP6068987A JPH07252156A (ja) 1994-03-15 1994-03-15 骨粗鬆症予防治療材

Publications (1)

Publication Number Publication Date
ES2179098T3 true ES2179098T3 (es) 2003-01-16

Family

ID=13389532

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95910802T Expired - Lifetime ES2179098T3 (es) 1994-03-15 1995-03-13 Agente de prevencion o de tratamiento de la osteoporosis.

Country Status (7)

Country Link
US (1) US5900255A (es)
EP (1) EP0753302B1 (es)
JP (1) JPH07252156A (es)
DE (1) DE69527140T2 (es)
ES (1) ES2179098T3 (es)
TW (1) TW400232B (es)
WO (1) WO1995024909A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10108647A (ja) * 1996-10-08 1998-04-28 Meiji Seika Kaisha Ltd 胃切除術後患者用ミネラル補給材
EP1060744B1 (en) * 1998-03-06 2005-11-23 Meiji Seika Kaisha, Ltd. Preventives/remedies for osteoporosis
US6241997B1 (en) 1998-03-16 2001-06-05 Smtm Group. Llc Chewable calcium supplement and method
GB9906009D0 (en) * 1999-03-16 1999-05-12 Nycomed Pharma As Product
US6436446B1 (en) * 1999-07-30 2002-08-20 Pharmavite Llc Composition for increasing bone density
US6846496B1 (en) 1999-10-15 2005-01-25 Orion Corporation Treatment of osteoporosis
EP1228764A1 (de) * 2001-02-01 2002-08-07 EnergyBalance AG Calciumkomposition mit Oligofructose
US6887897B2 (en) 2001-07-31 2005-05-03 Mission Pharmacal Company Calcium glutarate supplement and phosphorus binder
US8663679B2 (en) 2004-04-29 2014-03-04 Abbott Laboratories Compositions for improving breast health in women
US7435431B2 (en) * 2004-07-28 2008-10-14 Abbott Laboratories Method for controlling body weight in estrogen-insufficient women
US7601370B2 (en) * 2004-07-28 2009-10-13 Abbott Laboratories Method for controlling body weight in estrogen-insufficient women
US20060040001A1 (en) * 2004-07-28 2006-02-23 Johnson Catherine D Nutritional compositions and methods for treating or preventing osteoporosis
US20060029641A1 (en) * 2004-08-05 2006-02-09 Keller Nathan I Calcium and magnesium nutritional supplement
JP4588403B2 (ja) * 2004-10-04 2010-12-01 森永乳業株式会社 カルシウム・マグネシウム含有組成物の製造方法
JP2006111582A (ja) * 2004-10-15 2006-04-27 Suntory Ltd カルシウム含有顆粒の製造方法
JP5001847B2 (ja) * 2005-09-27 2012-08-15 旭化成ケミカルズ株式会社 セロオリゴ糖含有組成物
JP5349744B2 (ja) 2005-12-19 2013-11-20 松谷化学工業株式会社 ミネラル吸収促進剤、食品及び飼料
JP5122766B2 (ja) 2006-06-20 2013-01-16 ユニチカ株式会社 エコール産生促進組成物
JP5371415B2 (ja) * 2008-12-24 2013-12-18 王子コーンスターチ株式会社 骨密度減少抑制組成物
EP3752168A4 (en) * 2018-02-14 2021-10-13 Profeat Biotechnology Co. Ltd. USE OF FERROUS AMINO ACID CHELATE TO INCREASE CALCIUM ABSORPTION AND BONE MASS AND TREAT OSTEOPOROSIS
JP6931231B2 (ja) * 2018-02-28 2021-09-01 ふるさと和漢堂株式会社 イリコパウダーとフルクタンパウダーを含有させた栄養補助食品

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4689228A (en) * 1985-08-26 1987-08-25 University Patents, Inc. Enhanced absorption of dietary mineral components
US4867989A (en) * 1986-09-09 1989-09-19 Warner-Lambert Company Chewing gum mineral supplement
EP0346866A3 (en) * 1988-06-16 1990-07-11 Biochemie Gesellschaft M.B.H. Composition for the prophylaxis of osteoporosis
CA1337047C (en) * 1988-08-18 1995-09-19 Peter Dodd Cooper Gamma inulin compositions
JPH05238940A (ja) * 1991-05-22 1993-09-17 Pola Chem Ind Inc 生体への吸収率の高い速効用薬剤及びその製造方法
JPH04349868A (ja) * 1991-05-29 1992-12-04 Asahi Chem Ind Co Ltd ミネラル吸収促進剤
JPH04360664A (ja) * 1991-06-04 1992-12-14 Asahi Chem Ind Co Ltd ミネラル吸収性促進剤
JPH0640922A (ja) * 1991-07-19 1994-02-15 Morinaga Milk Ind Co Ltd カルシウム剤
JP2986133B2 (ja) * 1991-07-29 1999-12-06 ポーラ化成工業株式会社 ミネラル吸収促進剤
JP2596509B2 (ja) * 1992-12-11 1997-04-02 雪印乳業株式会社 新規なグルクロン酸含有オリゴ糖、その製造法及びその利用
JP3279695B2 (ja) * 1993-01-08 2002-04-30 雪印乳業株式会社 分岐ガラクトオリゴ糖を有効成分とするミネラル吸収促進剤
JP3279694B2 (ja) * 1993-01-08 2002-04-30 雪印乳業株式会社 ラクチュロースオリゴ糖を有効成分とするミネラル吸収促進剤
JP3462535B2 (ja) * 1993-08-31 2003-11-05 サントリー株式会社 ミネラル吸収促進組成物
US5431929A (en) * 1994-07-28 1995-07-11 Wm. Wrigley Jr. Company Chewing gum products using oligofructose

Also Published As

Publication number Publication date
EP0753302B1 (en) 2002-06-19
EP0753302A4 (en) 2000-02-16
EP0753302A1 (en) 1997-01-15
US5900255A (en) 1999-05-04
DE69527140T2 (de) 2003-02-20
DE69527140D1 (de) 2002-07-25
JPH07252156A (ja) 1995-10-03
WO1995024909A1 (fr) 1995-09-21
TW400232B (en) 2000-08-01

Similar Documents

Publication Publication Date Title
ES2179098T3 (es) Agente de prevencion o de tratamiento de la osteoporosis.
BR9806118A (pt) Processos para tratamento de pigmentação de pele
AR024874A1 (es) Composiciones bactericidas
BR9706369A (pt) Processo para tratamento de unhas humanas.
UY28213A1 (es) Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
ES2146300T3 (es) Utilizacion de composiciones antihelminticas para el tratamiento de infecciones causadas por anoplocephala perfoliata en equidos.
BR9916879A (pt) Composição e método para tratamento do câncer utilizando óleos essenciais vegetais naturais
ES2113635T3 (es) Aplicacion del riluzole en el tratamiento de lesiones neurologicas relacionadas con traumatismos.
MX151133A (es) Mejoras en dispositivo de sujecion para el tratamiento de huesos fracturados
CO5060498A1 (es) Composicion plaguicida sinergica que comprende emamectina (a)
ATE223213T1 (de) Konjugierte linoleinsäure zur erhaltung oder erhöhung des knochenmineraliengehaltes
ID28949A (id) Artikel-artikel penyerap yang menjaga atau memperbaiki kesehatan kulit
BR9809932A (pt) Métodos para tratamento de distúrbios trombóticos
ATE305300T1 (de) Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumoren
AR005861A1 (es) Una composicion liquida de limpieza de la piel ,y un metodo para potenciar el efecto antimicrobiano de formulaciones de limpieza de la piel
PL310475A1 (en) Application of anticonvulsants in treating neuro-aids diseases
ES2178048T3 (es) Uso de rifaximina como medicamento para el tratamiento de diarrea por criptosporidiosis.
BR0107667A (pt) Composto de linezolida em forma de cristal que e farmaceuticamente útil como agente antibacteriano e método de preparação do mesmo
BR0010531A (pt) Composições e usos de et743 para tratamento de câncer
PE20011280A1 (es) Articulos que tienen un sistema de control de olor que comprende un polisacarido cationico y un agente de control de olor
PE30695A1 (es) Composiciones orales
DE69825279D1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
BR9810981A (pt) Medicamento contendo ioimbina e arginina para tratamento de disfunção erétil
ES2178405T3 (es) Uso de selegilina o de desmetilselegilina para tratar heridas, quemaduras y lesiones cutaneas.
ES2078904T3 (es) Nuevos derivados de neplanocina.